Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents

Trial Profile

Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Daclatasvir/sofosbuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Antivirals
  • Indications Fibrosis; Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ANRSCO23CUPILT
  • Most Recent Events

    • 12 Sep 2017 Results (n=25) assessing HCV recurrence after combined liver-kidney transplantation, published in the American Journal of Transplantation.
    • 27 Jun 2016 Results (n=125) published in the Liver Transplantation
    • 01 Jun 2016 Results assessing SVR12 in patients with HCV recurrence (n = 137) published in the Journal of Hepatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top